|Mr. James A. Schoeneck||Chairman||751.63k||934.26k||1958|
|Mr. Pat Cotroneo||Chief Financial Officer||773.57k||3.79M||1964|
|Dr. K. Peony Yu||Exec. Advisor to Chief Exec. Officer||926.21k||396.02k||1962|
|Dr. Elias Kouchakji||Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance||863.19k||471.6k||1956|
|Ms. Christine L. Chung||Sr. VP of China Operations||701.09k||2.39M||1968|
|Mr. Enrique A. Conterno||CEO & Director||N/A||N/A||1967|
|Dr. Barry A. Berkowitz||Founder||N/A||N/A||N/A|
|Dr. Michael J. Martinelli||Sr. VP of Technical Devel.||N/A||N/A||N/A|
|Dr. Percy Carter M.B.A., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Karen L. Bergman||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
FibroGen, Inc.’s ISS governance QualityScore as of 2 December 2020 is 5. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 8; Compensation: 8.